News
WellDyne Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care
New PrismRA® blood test enables providers to identify optimal approach to rheumatoid arthritis treatment FEBRUARY 11, 2021 – WALTHAM, MA...
Scipher Medicine Brings Precision Medicine Platform to Patient-Centered MIT Initiative
First-Of-Its-Kind Lab Test Helps Guide Targeted Treatment Decisions in Rheumatoid Arthritis FEBRUARY 3, 2021 – WALTHAM, MA – Scipher Medicine, a...
Precision medicine arrives in RA: Biomarker test predicts TNF inhibitor response
By: Rob Volansky If there was any question about whether rheumatologists would utilize an effective biomarker that can predict response...
New Study Demonstrates Clinical Utility of PrismRA Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients
Nine out of 10 responding rheumatologists stated the test would increase their confidence when making prescribing decisions WALTHAM, Mass. –...
18th U.S. Surgeon General Joins Scipher Medicine
Dr. Regina Benjamin to Advise on Access to Precision Medicine Driving Better Health Outcomes for Patients with Autoimmune Diseases OCTOBER...
Scipher Medicine and Ambry Genetics Partner to Bring Precision Medicine Test for Rheumatoid Arthritis to Market
PrismRA® first-of-its-kind molecular signature test validated in Ambry’s central laboratory. Partnership provides infrastructure for rapid scaling and patient accessibility.
Pioneering precision medicine in rheumatoid arthritis
Scipher Medicine is a spin-out of Northeastern University founded on the basis of, first, building a map of human biology...
New Strategy for Avoiding Waste and Improving Response for Highest Cost Therapies in Rheumatoid Arthritis
AMCP Science & Innovation Theater Webinar Speakers: James T. Kenney, MBA, RPh, President, JTKENNEY, LLC Alif Saleh, CEO, Scipher Medicine...
Scipher Medicine Announces Publication of Clinical Study Validating PrismRA, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in Patients with Rheumatoid Arthritis
PrismRA identifies patients 6.6 times less likely to respond to TNFi therapy JULY 28, 2020- WALTHAM, MA- (Business Wire)- Scipher Medicine,...
Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients
Abstract Objectives: For rheumatoid arthritis (RA) patients failing to achieve treatment targets with conventional synthetic disease-modifying antirheumatic drugs, tumor necrosis factor...